drugset / Trial / NCT04585490
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to test whether or not number of circulating cancer cells detected in the blood can be decreased the by combining the standard treatment (durvalumab) with Tremelimumab and additional chemotherapy
Timeline
- Start
- 2021-08-25
- Primary completion
- 2026-08
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 750 mg | — |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | Durvalumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | — |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | — |
| Subject | Tremelimumab | Monoclonal antibody | 75 mg | Intravenous |